-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on ImmunityBio, Raises Price Target to $12

Benzinga·03/04/2026 13:53:02
Listen to the news
Piper Sandler analyst Edward Tenthoff reiterates ImmunityBio (NASDAQ:IBRX) with a Overweight and raises the price target from $7 to $12.